---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117567"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:47:39.124146+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront

## Summary
- Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.
- $150 million upfront payment; up to $2.1B in development, regulatory, and sales milestones starting at Phase 2.
- Monte Rosa completes ongoing Phase 1 study; Novartis handles all subsequent development from Phase 2 onward.
- Monte Rosa eligible for tiered royalties on ex-U.S. net sales and 30% U.S. profit/loss share from Phase 3 onward.
- Deal validates Monte Rosa's QuEEN discovery engine and extends operational runway; closing subject to HSR clearance.

## SEC filing metadata
- accession: 0000950170-24-117567
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024117567/0000950170-24-117567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024117567/glue-20241025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117567
- JSON: https://secwatch.observer/filing/0000950170-24-117567.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.